VisualAbstract Association of Initial DiseaseModifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

#VisualAbstract: Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

11:00 EST 27 Jan 2019 | 2 Minute Medicine

1. In this case-control cohort study, treatment with glatiramer acetate, interferon-beta, fingolimod, alemtuzumab, and natalizumab all led to reduced conversion to secondary progressive multiple sclerosis (MS) compared to no Disease-Modifying Treatment (DMT). 2. Treatment with fingolimod, alemtuzumab, and natalizumab had reduced conversion to secondary progressive MS compared to glatiramer acetate and interferon-beta. Evidence Rating Level: […]

Source: 2 Minute Medicine

More From BioPortfolio on "#VisualAbstract: Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis"